Homology Medicines announces publication of in vivo gene editing data with nuclease-free technology

Homology Medicines, Inc., a genetic medicines company, announced today a peer-reviewed publication demonstrating that Homology’s technology induces efficient and precise in vivo gene editing. The publication, by senior author Saswati Chatterjee, Ph.D., Department of Surgery, member of the Beckman Research Institute at City of Hope in California, and scientific co-founder of Homology, also highlights the platform’s use of homologous recombination, the cells’ natural DNA correction pathway, for nuclease-free gene editing.

Go to Source

(Visited 4 times, 1 visits today)

Site Footer

Sliding Sidebar